

# **Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges**

<https://marketpublishers.com/r/G899C6199FEEN.html>

Date: December 2018

Pages: 0

Price: US\$ 1,990.00 (Single User License)

ID: G899C6199FEEN

## **Abstracts**

Vitiligo is a long-term skin disease in which patches of the skin lose their color. The skin patches affected by the disease Vitiligo become white. This happens because melanocytes within the skin die off. The skin pigmentation, melanin, due to which skin has its color, protection from sun UV rays this all happens because of melanocytes cells. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of Vitiligo drugs are some of the driving force for the growth of this market. However, shortage of dermatologists and available treatments having longer duration of times are major challenges for the growth of this market. According to Renub Research global Vitiligo market will be US\$ 2.4 Billion by the year 2024.

Vitiligo disease prevalence varies between race, regions and countries. It is expected that overall prevalence fall between 1-2 percent of the total population. Although Vitiligo disease can arise at any age, it mostly occurs to young and middle age people. At present globally over 21 Million people has suffered from this diseases. There are number of drugs manufactures working for Vitiligo drugs development across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek

Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc. and their Vitiligo drugs development are in various stages.

Renub Research report titled “Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges” provides a complete analysis of global vitiligo drugs market.

India and China are Key Contributors in the Global Vitiligo Patient Population

Vitiligo patient’s population is growing across all parts of the world. Patient’s growth rates varies in the countries covered in the report United States, United Kingdom, France, Germany, Italy, India, China and Japan. India and China are key contributors in the global vitiligo patient population.

Vitiligo Pipe Line Drugs are Key Strength for this Market Place

In the global vitiligo market, vitiligo pipe line drugs will play the major role for the growth of this market. At present several drugs such as ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001 etc. are in preclinical, IND, Phase I, Phase II and Phase III stage.

Key Drugs Development Companies are working in this Market Place

Key drugs development companies are working in this market place across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc.

Segments - Global Vitiligo Market

Vitiligo Patients Population

Vitiligo Market

## Countries - Global Vitiligo Market

United States

United Kingdom

France

Germany

Italy

India

China

Japan

## Global Vitiligo Market – Drugs Profile Covered

ARN-4079

ATI-502

AX-1602

BOS-47

CCP-070

Cerdulatinib (RVT-502)

HuABC-2

Abatacept

Topical Ruxolitinib

VLRX-001

## Companies Covered

AXIM Biotechnologies

Incyte Corporation

Bristol-Myers Squibb

Clinuvel Pharmaceuticals

## Each Company Covered in this Report has Following Details

Company Overview

Company Initiatives

Financial Insight

## Contents

### **1. INTRODUCTION**

1.1 Market Definition

### **2. RESEARCH METHODOLOGY**

### **3. EXECUTIVE SUMMARY**

### **4. GLOBAL VITILIGO PATIENT NUMBERS & MARKET**

4.1 Vitiligo Patients Numbers

4.2 Vitiligo Market

### **5. SHARE – GLOBAL VITILIGO PATIENT NUMBERS & MARKET**

5.1 Vitiligo Patient Numbers Share

5.2 Vitiligo Market Share

### **6. UNITED STATES**

6.1 Vitiligo Patient Numbers

6.2 Vitiligo Market

### **7. UNITED KINGDOM**

7.1 Vitiligo Patient Numbers

7.2 Vitiligo Market

### **8. FRANCE**

8.1 Vitiligo Patient Numbers

8.2 Vitiligo Market

### **9. GERMANY**

9.1 Vitiligo Patient Numbers

## 9.2 Vitiligo Market

## **10. ITALY**

### 10.1 Vitiligo Patient Numbers

### 10.2 Vitiligo Market

## **11. INDIA**

### 11.1 Vitiligo Patient Numbers

### 11.2 Vitiligo Market

## **12. CHINA**

### 12.1 Vitiligo Patient Numbers

### 12.2 Vitiligo Market

## **13. JAPAN**

### 13.1 Vitiligo Patient Numbers

### 13.2 Vitiligo Market

## **14. VITILIGO PIPE LINE DRUGS**

### 14.1 ARN-4079

### 14.2 ATI-502

### 14.3 AX-1602

### 14.4 BOS-475

### 14.5 CCP-070

### 14.6 Cerdulatinib (RVT-502)

### 14.7 HuABC-2

### 14.8 Abatacept

### 14.9 Topical Ruxolitinib

### 14.10 VLRX-001

## **15. CLINICAL STUDY OF VITILIGO MARKET**

## **16. GROWTH DRIVERS**

- 16.1 Growing Importance of Aesthetic Appeal
- 16.2 World Vitiligo Day: Increases Vitiligo Awareness

## **17. GLOBAL VITILIGO MARKET – CHALLENGES**

- 17.1 Shortage of Dermatologists
- 17.2 Available Treatments are Not Much Effective

## **18. AXIM BIOTECHNOLOGIES, INC.**

- 18.1 Company Overview
- 18.2 Initiatives
  - 18.2.1 Point
  - 18.2.2 Point
  - 18.2.3 Point
- 18.3 Financial Insight

## **19. INCYTE CORPORATION**

- 19.1 Company Overview
- 19.2 Initiatives
  - 19.2.1 Point
  - 19.2.2 Point
- 19.3 Financial Insight

## **20. BRISTOL-MYERS SQUIBB**

- 20.1 Company Overview
- 20.2 Initiatives
  - 20.2.1 Point
  - 20.2.2 Point
- 20.3 Financial Insight

## **21. CLINUVEL PHARMACEUTICALS LTD**

- 21.1 Company Overview
- 21.2 Company Initiatives
  - 21.2.1 Point
  - 21.2.2 Point

## 21.3 Financial Insight



## List Of Figures

### LIST OF FIGURES:

- Figure 4 1: Global – Vitiligo Patients Population (Thousand), 2012 – 2017
- Figure 4 2: Global – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
- Figure 4 3: Global – Vitiligo Market (Million US\$), 2012 – 2017
- Figure 4 4: Global – Forecast for Vitiligo Market (Million US\$), 2018 – 2024
- Figure 5 1: Global – Vitiligo Patients Population Share (Percent), 2012 – 2017
- Figure 5 2: Global – Forecast for Vitiligo Patients Population Share (Percent), 2018 – 2024
- Figure 5 3: Global – Vitiligo Market Share (Percent), 2012 – 2017
- Figure 5 4: Global – Forecast for Vitiligo Market Share (Percent), 2018 – 2024
- Figure 6 1: United States – Vitiligo Patients Population (Thousand), 2012 – 2017
- Figure 6 2: United States – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
- Figure 6 3: United States – Vitiligo Market (Million US\$), 2012 – 2017
- Figure 6 4: United States – Forecast for Vitiligo Market (Million US\$), 2018 – 2024
- Figure 7 1: United Kingdom – Vitiligo Patients Population (Thousand), 2012 – 2017
- Figure 7 2: United Kingdom – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
- Figure 7 3: United Kingdom – Vitiligo Market (Million US\$), 2012 – 2017
- Figure 7 4: United Kingdom – Forecast for Vitiligo Market (Million US\$), 2018 – 2024
- Figure 8 1: France – Vitiligo Patients Population (Thousand), 2012 – 2017
- Figure 8 2: France – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
- Figure 8 3: France – Vitiligo Market (Million US\$), 2012 – 2017
- Figure 8 4: France – Forecast for Vitiligo Market (Million US\$), 2018 – 2024
- Figure 9 1: Germany – Vitiligo Patients Population (Thousand), 2012 – 2017
- Figure 9 2: Germany – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
- Figure 9 3: Germany – Vitiligo Market (Million US\$), 2012 – 2017
- Figure 9 4: Germany – Forecast for Vitiligo Market (Million US\$), 2018 – 2024
- Figure 10 1: Italy – Vitiligo Patients Population (Thousand), 2012 – 2017
- Figure 10 2: Italy – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
- Figure 10 3: Italy – Vitiligo Market (Million US\$), 2012 – 2017
- Figure 10 4: Italy – Forecast for Vitiligo Market (Million US\$), 2018 – 2024
- Figure 11 1: India – Vitiligo Patients Population (Thousand), 2012 – 2017
- Figure 11 2: India – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
- Figure 11 3: India – Vitiligo Market (Million US\$), 2012 – 2017

- Figure 11 4: India – Forecast for Vitiligo Market (Million US\$), 2018 – 2024
- Figure 12 1: China – Vitiligo Patients Population (Thousand), 2012 – 2017
- Figure 12 2: China – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
- Figure 12 3: China – Vitiligo Market (Million US\$), 2012 – 2017
- Figure 12 4: China – Forecast for Vitiligo Market (Million US\$), 2018 – 2024
- Figure 13 1: Japan – Vitiligo Patients Population (Thousand), 2012 – 2017
- Figure 13 2: Japan – Forecast for Vitiligo Patients Population (Thousand), 2018 – 2024
- Figure 13 3: Japan – Vitiligo Market (Million US\$), 2012 – 2017
- Figure 13 4: Japan – Forecast for Vitiligo Market (Million US\$), 2018 – 2024
- Figure 14 1: Vitiligo Pipe Line Drug – ARN-4079 Status (2018)
- Figure 14 2: Vitiligo Pipe Line Drug – ATI-502 Status (2018)
- Figure 14 3: Vitiligo Pipe Line Drug – AX-1602 Status (2018)
- Figure 14 4: Vitiligo Pipe Line Drug – BOS-475 Status (2018)
- Figure 14 5: Vitiligo Pipe Line Drug – CCP-070 Status (2018)
- Figure 14 6: Vitiligo Pipe Line Drug – Cerdulatinib (RVT-502) Status (2018)
- Figure 14 7: Vitiligo Pipe Line Drug – HuABC-2 Status (2018)
- Figure 14 8: Vitiligo Pipe Line Drug – Abatacept Status (2018)
- Figure 14 9: Vitiligo Pipe Line Drug – Topical Ruxolitinib Status (2018)
- Figure 14 10: Vitiligo Pipe Line Drug – VLRX-001 Status (2018)
- Figure 18 1: Axim Biotechnologies, Inc – Global Sales (US\$), 2015 - 2017
- Figure 18 2: Axim Biotechnologies, Inc – Forecast for Global Sales (US\$), 2018 - 2024
- Figure 19 1: Incyte Corporation – Global Sales (Million US\$), 2012 - 2017
- Figure 19 2: Incyte Corporation – Forecast for Global Sales (Million US\$), 2018 - 2024
- Figure 20 1: Bristol-Myers Squibb – Global Sales (Million US\$), 2012 - 2017
- Figure 20 2: Bristol-Myers Squibb – Forecast for Global Sales (Million US\$), 2018 - 2024
- Figure 21 1: Clinuvel Pharmaceuticals Limited – Global Sales (Thousand US\$), 2013 - 2017
- Figure 21 2: Clinuvel Pharmaceuticals Limited – Forecast for Global Sales (Thousand US\$), 2018 - 2024

## List Of Tables

### LIST OF TABLES:

Table 15-1: Global – Vitiligo Market Clinical Study, 2018

## I would like to order

Product name: Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges

Product link: <https://marketpublishers.com/r/G899C6199FEEN.html>

Price: US\$ 1,990.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G899C6199FEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970